Section/topic | No. | Checklist item | Information reported | Line number(s) | |
---|---|---|---|---|---|
Yes | No | ||||
Administrative information | |||||
Title | |||||
Identification | 1a | Identify the report as a protocol of a systematic review | ☒ | ☐ | 4 |
Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | ☐ | ☒ | |
Registration | 2 | If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract | ☒ | ☐ | 54 |
Authors | |||||
Contact | 3a | Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author | ☒ | ☐ | 6, 19 |
Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | ☒ | ☐ | 488 |
Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | ☒ | ☐ | 420 |
Support | |||||
Sources | 5a | Indicate sources of financial or other support for the review | ☒ | ☐ | 484 |
Sponsor | 5b | Provide name for the review funder and/or sponsor | ☐ | ☒ | No sponsor |
Role of sponsor/funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | ☐ | ☒ | No sponsor |
Introduction | |||||
Rationale | 6 | Describe the rationale for the review in the context of what is already known | ☒ | ☐ | 61 |
Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | ☒ | ☐ | 152 |
Methods | |||||
Eligibility criteria | 8 | Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review | ☒ | ☐ | 166 |
Information sources | 9 | Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage | ☒ | ☐ | 242 |
Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | ☒ | ☐ | 253, 683 |
Study records | |||||
Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | ☒ | ☐ | 269 |
Selection process | 11b | State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) | ☒ | ☐ | 277 |
Data collection process | 11c | Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | ☒ | ☐ | 289 |
Data items | 12 | List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications | ☒ | ☐ | 303 |
Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | ☒ | ☐ | 314 |
Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | ☒ | ☐ | 335 |
Data | |||||
Synthesis | 15a | Describe criteria under which study data will be quantitatively synthesized | ☒ | ☐ | 355 |
15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I 2, Kendall’s tau) | ☒ | ☐ | 360, 390 | |
15c | Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression) | ☒ | ☐ | 409 | |
15d | If quantitative synthesis is not appropriate, describe the type of summary planned | ☒ | ☐ | 368 | |
Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies) | ☒ | ☐ | 337, 418 |
Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (e.g., GRADE) | ☒ | ☐ | 348 |